ClinicalTrials.gg
CompletedNCT06288516BREATHUpdated Oct 28, 2026

BenRalizumab Effect on Airway Remodeling in Severe asTHma

A Phase 4 interventional study of Benralizumab 30 mg/ml in Asthma; Eosinophilic and Airway Remodeling, sponsored by Aristotle University Of Thessaloniki. Completed at 1 site in Greece. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Aristotle University Of Thessaloniki · Phase 4, Interventional, and Treatment

How we know

Updated Oct 28, 2026Now CompletedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Response to biologic therapies in severe asthma is variable, with patients being either non-responders, responders or super-responders. There is currently no explanation for this broad variation in response. It is important to examine whether these patients have distinct characteristics that could help the treating physician in making the correct diagnosis in clinical practice.

Aim of this clinical study is to evaluate the efficacy of benralizumab, a humanized an anti-interleukin 5 receptor α monoclonal antibody in patients with severe eosinophilic asthma and to evaluate airway remodeling before and after benralizumab treatment.

Hypothesis Identification of pathological and clinical characteristics in patients with severe eosinophilic asthma after benralizumab treatment regarding the airway remodeling, inflammatory cells, and other biomarkers on a long-term basis.

Research questions Is there any improvement in airway remodeling? Are there any biomarkers to predict response to benralizumab treatment in severe eosinophilic asthmatic patients?

Read the detailed description

Interleukin (IL)-5 is the main cytokine responsible for the activation of eosinophils, hence therapeutic strategies have been investigated and developed for clinical use. Biologics targeting IL-5 and its receptor have been recently approved and used as add-on therapy for severe eosinophilic asthma resulting in a reduction in the circulating eosinophil count, improvement in lung function and exacerbation reduction in patients with severe asthma.

Response to biologic therapies in severe asthma is variable, with patients being either non-responders, responders or super-responders. There is currently no explanation for this broad variation in response. It is important to examine whether these patients have distinct characteristics that could help the treating physician in making the correct diagnosis in clinical practice.

Aim of this clinical study is to evaluate the efficacy of benralizumab, a humanized an anti-interleukin 5 receptor α monoclonal antibody in patients with severe eosinophilic asthma and to evaluate airway remodeling before and after benralizumab treatment. Every patient will be a control to himself by comparing baseline's biomarker measurements of each patient to the following timepoint's measurements. However, we have added 10 severe asthmatics with no intervention, receiving standard of care as control groups to make more comparisons.

Several methods are used to investigate airway inflammation: direct measurements (like bronchial biopsies or bronchoalveolar lavages) and indirect methods (like symptom assessment, blood sample analysis and lung function tests). The direct techniques have the advantage of reliably assessing the airway inflammation, but they are invasive and not feasible at large scale because of patient discomfort and the risk incurred. As for the indirect methods, they poorly correlate with the direct assessment of airway inflammation.

In this study, among patients' clinical characteristics spirometry, biomarkers of inflammation such as blood eosinophils, Fractional Exhaled Nitric Oxide (FeNO), immunoglobulin E (IgE) levels), and airway remodeling via bronchoscopy will be evaluated. The precise effects of increased airway smooth muscle area on airway narrowing are not known and may vary with disease severity. In addition, biomarkers of inflammation will also be evaluated before and after 52-week of benralizumab treatment in biological fluids (serum and bronchial samples). Biomarkers of inflammation are very important to identify treatment response.

Besides, asthmatic disease is characterized by a chronic mucosal inflammatory process, which results in irreversible changes of the bronchial wall, known today as "bronchial remodeling". Glandular and smooth muscle fibers hyperplasia and/or hypertrophy, goblet cells hyperplasia, and variable thickening of basement membrane (BM) present under the respiratory epithelium are part of these morphological changes. the changes generated at the epithelium-connective interface account for an "adaptive response" to inflammatory stress and sporadic bronchoconstriction. However, current data on BM reactivity in asthmatic patient are still incomplete for an accurate assessment of its involvement in pathogenesis and specifically in bronchial wall remodeling, mainly as collagen deposits in lamina reticularis are not correlated to the degree of disease severity.

Moreover, it is increasingly evident that severe asthma is not a single disease, as evidenced by the variety of clinical presentations, physiologic characteristics, and outcomes seen in patients with asthma. To better understand this heterogeneity, the concept of asthma phenotyping and endotyping has emerged. Phenotyping integrates both biological and clinical features, from molecular, cellular, morphologic, and functional to patient-oriented characteristics with the goal to improve therapy. Ultimately, these phenotypes evolve into asthma "endotypes," which combine clinical characteristics with identifiable mechanistic pathways. Biomarkers, defined as characteristics that can be objectively measured and serve as an indicator of underlying biological processes or pathogenesis, are crucial in defining phenotypes and endotypes. In asthma, genetic polymorphisms, measures of airway physiology, and levels of inflammatory mediators in urine, blood, sputum, tissue, exhaled gas, and breath condensate have all been studied as potential markers to improve and objectify asthma diagnosis and management. Developing such tools will allow us to phenotype and endotype the various clinical patterns described in asthma, with the ultimate goal of tailoring therapy based on a specific biomarker profile. Biomarkers can then be used to help better understand the pharmacologic response to an intervention and adjust therapy accordingly.

Biomarkers have been critical for studies of disease pathogenesis and the development of new therapies in severe asthma. In particular, biomarkers of type 2 inflammation have proven valuable for endotyping and targeting new biological agents. Because of these successes in understanding and marking type 2 inflammation, lack of knowledge regarding non-type 2 inflammatory mechanisms in asthma will soon be the major obstacle to the development of new treatments and management strategies in severe asthma. Other potential biomarkers include innate lymphoid cells, IL-33 or thymic stromal lymphopoietin.

02

Conditions studied

  • Asthma; Eosinophilic
  • Airway Remodeling

Keywords

  • severe asthma
  • airway remodeling
  • eosinophilic
  • biomarkers
  • bronchoscopy
03

In context

Airway Remodeling

28 studies on the registry are indexed under Airway Remodeling; 5 are open to participants now.

This study's enrollment of 36 is close to the median of 40 across 21 interventional studies indexed under Airway Remodeling.

Browse Airway Remodeling studies →

Lead sponsor

Aristotle University Of Thessaloniki is the lead sponsor of 282 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained at screening visit, before any assessment will be performed. Subjects should be able to provide informed written consent (study participation informed consent form): Able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form. Subjects must be able to read, comprehend, and write at a level sufficient to complete study related materials.
  • Confirmed severe asthma diagnosis and treatment requirements according to American Thoracic Society(ATS)/European Respiratory Society (ERS) guidelines and Global Initiative for Asthma (GINA) 2023.
  • Blood eosinophils ≥150cells/ul at screening visit or ≥300cells/ul the last 12 months.
  • Patients with history ≥ 1 exacerbation the previous year under the treatment of high dose of inhaled (ICS)+LABA±LAMA or receiving oral/systemic corticosteroids at least 3 days. For subjects on maintenance oral corticosteroids, an exacerbation requiring oral corticosteroids was defined as the use of oral/systemic corticosteroids at least double the existing dose for at least 3 days.
  • Meet requirements for biologic therapy with Benralizumab.

Exclusion criteria

Exclusion Criteria:

  • Asthma exacerbation, within 6 weeks prior to screening that required hospitalization or emergency room visit.
  • Prior use of other biologics that has potential to interfere/ affect disease progression.
  • Pregnant or nursing women, or women of .
  • History of of any organ system or any other serious co-morbidities defined by the treating physician.
  • Patients with a history of conditions other than asthma that could result in elevated eosinophils (e.g. hypereosinophilic syndromes, Churg-Strauss Syndrome, eosinophilic esophagitis).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Benralizumab Arm A

    Benralizumab (30mg) administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks.

    Drug: Benralizumab 30 mg/ml

  • No intervention
    No intervention Arm B

    No intervention. Standard of care as treatment.

Interventions

  • DrugBenralizumab 30 mg/ml

    Drug page: BenralizumabStudies of BenralizumabBenralizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks

    Also known as: biological

06

What researchers measure

Primary outcomes

  1. Change in sub-basement membrane thickness

    The identification of clinical characteristics of non-responders and super-responders. Any improvement in this parameter will be measured as change from baseline compared to measurement after 1 year of treatment.

    Time frame: through study completion, 52 weeks

  2. Change in airway smooth muscle area

    The identification of clinical characteristics of non-responders and super-responders. Any improvement in this parameter will be measured as change from baseline compared to measurement after 1 year of treatment.

    Time frame: through study completion, 52 weeks

  3. Change in airway smooth muscle layer thickness

    The identification of clinical characteristics of non-responders and super-responders. Any improvement in this parameter will be measured as change from baseline compared to measurement after 1 year of treatment.

    Time frame: through study completion, 52 weeks

  4. Change in submucosal eosinophil number

    The identification of clinical characteristics of non-responders and super-responders. Any improvement in this parameter will be measured as change from baseline compared to measurement after 1 year of treatment.

    Time frame: through study completion, 52 weeks

  5. Change in epithelial integrity

    The identification of clinical characteristics of non-responders and super-responders. Any improvement in this parameter will be measured as change from baseline compared to measurement after 1 year of treatment.

    Time frame: through study completion, 52 weeks

  6. Change in collagen thickness

    The identification of clinical characteristics of non-responders and super-responders. Any improvement in this parameter will be measured as change from baseline compared to measurement after 1 year of treatment, measured by electron microscopy.

    Time frame: through study completion, 52 weeks

Secondary outcomes

  1. Change of cytokine and protein levels

    To identify any possible biomarkers of response of non-responders versus super-responders in different biological fluids as peripheral blood and bronchial washing. The identification of clinical characteristics of non-responders and super-responders. Change from baseline compared to measurements after 6 months and after 1 year of benralizumab treatment.

    Time frame: through study completion, 52 weeks

  2. Change in exacerbation rate

    Measurement of the change in exacerbation rate in each severe eosinophilic asthmatic patient under benralizumab treatment for 52 weeks of treatment.

    Time frame: through study completion, 52 weeks

  3. Change in blood eosinophil levels

    Measurement of the change in blood eosinophil levels in each severe eosinophilic asthmatic patient under benralizumab treatment for 52 weeks of treatment.

    Time frame: through study completion, 52 weeks

  4. dentification of clinical characteristics of response, change in Forced Expiratory Volume (FEV1)

    The identification of clinical characteristics of non-responders and super-responders. FEV1 change from baseline, before treatment initiation, compared to measurements every 3 months until 1 year of treatment. FEV1 is the maximal amount of air you can forcefully exhale in one second measured by spirometry.

    Time frame: through study completion, 52 weeks

07

Study locations

1 site
  • Pulmonary Clinic, Aristotle University of Thessaloniki, George Papanikolaou Hospital
    Thessaloniki, Thessaloniki 57010, Greece
08

References and documents

Publications

  • Kuo CW, Liao XM, Huang YC, Chang HY, Shieh CC. Bronchoscopy-guided bronchial epithelium sampling as a tool for selecting the optimal biologic treatment in a patient with severe asthma: a case report. Allergy Asthma Clin Immunol. 2019 Nov 27;15:76. doi: 10.1186/s13223-019-0378-6. eCollection 2019. PubMed 31798645 ↗
  • Bara I, Ozier A, Tunon de Lara JM, Marthan R, Berger P. Pathophysiology of bronchial smooth muscle remodelling in asthma. Eur Respir J. 2010 Nov;36(5):1174-84. doi: 10.1183/09031936.00019810. PubMed 21037369 ↗
  • Rasmussen F, Taylor DR, Flannery EM, Cowan JO, Greene JM, Herbison GP, Sears MR. Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: a longitudinal population study from childhood to adulthood. Am J Respir Crit Care Med. 2002 Jun 1;165(11):1480-8. doi: 10.1164/rccm.2108009. PubMed 12045120 ↗
  • Yancey SW, Keene ON, Albers FC, Ortega H, Bates S, Bleecker ER, Pavord I. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol. 2017 Dec;140(6):1509-1518. doi: 10.1016/j.jaci.2017.10.005. PubMed 29221581 ↗
  • Siddiqui S, Bachert C, Bjermer L, Buchheit KM, Castro M, Qin Y, Rupani H, Sagara H, Howarth P, Taille C. Eosinophils and tissue remodeling: Relevance to airway disease. J Allergy Clin Immunol. 2023 Oct;152(4):841-857. doi: 10.1016/j.jaci.2023.06.005. Epub 2023 Jun 19. PubMed 37343842 ↗
  • Berair R, Hartley R, Mistry V, Sheshadri A, Gupta S, Singapuri A, Gonem S, Marshall RP, Sousa AR, Shikotra A, Kay R, Wardlaw A, Bradding P, Siddiqui S, Castro M, Brightling CE. Associations in asthma between quantitative computed tomography and bronchial biopsy-derived airway remodelling. Eur Respir J. 2017 May 1;49(5):1601507. doi: 10.1183/13993003.01507-2016. Print 2017 May. PubMed 28461289 ↗

Individual participant data

Plan to share: Yes — A reference of the published article will be shared here.

Supporting information: Study protocol, Clinical study report

Time frame: Starting 9 months after publication and ending 36 months following article publication.

Access criteria: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose. For individual participant data meta-analysis, data will be shared. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (Link to be provided).

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2024 to primary completion in Aug 2026, 29 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Dec 2025 → Aug 2026 and completion Jun 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2024
First posted
Mar 1, 2024
StartActual
Mar 1, 2024
Primary completionActual
Aug 31, 2026was Dec 2025
CompletionActual
Oct 27, 2026was Jun 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 28, 2026
Sites
1 site added, 1 site removed
Show site
  • Pulmonary Clinic, Aristotle University of Thessaloniki, George Papanikolaou Hospital · Thessaloniki, Greece
Show 1 removed
  • Pulmonary Clinic, Aristotle University of Thessaloniki, George Papanikolaou Hospital · Thessaloniki, Greece
Oct 28, 2026
Primary completion
Dec 31, 2025→Aug 31, 2026 (actual)
Oct 28, 2026
Study completion
Jun 1, 2026→Oct 27, 2026 (actual)
Oct 28, 2026
Enrollment
45 (estimated)→36 (actual)
Oct 28, 2026
Sponsor
Collaborators added: National and Kapodistrian University of Athens; collaborators removed: Pulmonary Clinic, Aristotle University of Thessaloniki, Greece·2nd Pulmonary Clinic, Kapodistrian University of Athens·Pulmonary and Respiratory Failure Department, National and Kapodistrian University of Athens
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Pulmonary Clinic, Aristotle University of Thessaloniki, George Papanikolaou Hospital · Thessaloniki, Greece
    Show 1 removed
    • Pulmonary Clinic, Aristotle University of Thessaloniki, George Papanikolaou Hospital · Thessaloniki, Greece
    Primary completion Dec 31, 2025→Aug 31, 2026 (now actual)
    Study completion Jun 1, 2026→Oct 27, 2026 (now actual)
    Enrollment 45 (estimated)→36 (actual)
    Sponsor Collaborators added: National and Kapodistrian University of Athens; collaborators removed: Pulmonary Clinic, Aristotle University of Thessaloniki, Greece·2nd Pulmonary Clinic, Kapodistrian University of Athens·Pulmonary and Respiratory Failure Department, National and Kapodistrian University of Athens
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06288516
Collaborators
Pulmonary Clinic, University of Ioannina, Pulmonary Clinic, Democritus University of Thrace, National and Kapodistrian University of Athens, University Hospital of Crete, University Hospital of Patras
Responsible party
Kalliopi Domvri (Academic Fellow in the laboratory of Histology-Embryology, Aristotle University Of Thessaloniki) — Principal investigator
First posted
Mar 1, 2024
Start date
Mar 1, 2024
Primary completion
Aug 31, 2026
Completion
Oct 27, 2026
Last update
Oct 28, 2026

Study contacts

Kalliopi Domvri, Dr
principal investigator · Aristotle University Of Thessaloniki

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion